Symphogen Revenue and Competitors
Estimated Revenue & Valuation
- Symphogen's estimated annual revenue is currently $43.4M per year.
- Symphogen's estimated revenue per employee is $193,750
- Symphogen's total funding is $375.2M.
Employee Data
- Symphogen has 224 Employees.
- Symphogen grew their employee count by 8% last year.
Symphogen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Symphogen?
Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its pipeline, currently has two product candidates in the clinic, and is researching promising novel immuno-oncology opportunities.“
keywords:N/A
$375.2M
Total Funding
224
Number of Employees
$43.4M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Symphogen News
This new system adds to Symphogen's range of High-Resolution Accurate Mass (HRAM) mass spectrometry technologies, including Thermo Scientific Q...
COPENHAGEN, Denmark–(BUSINESS WIRE)–Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent m ...
Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibody mixtures, closed a €67.5m convertible debt facility from existing investors. The round, which brought total pro-forma cash resources to a total of €110m, was led by Novo A/S and the Danish pension f ...
Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the closing of a EUR 67.5 million convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be ...
Other Companies in Somerville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 227 | -8% | N/A |
#2 | $95.2M | 268 | 20% | N/A |
#3 | $61.9M | 281 | -1% | $13M |
#4 | $106.4M | 295 | 8% | N/A |
#5 | $300M | 296 | 8% | N/A |